A5100440100- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Peptidase Inhibition and Analysis
- Pancreatic and Hepatic Oncology Research
- Cancer Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Ferroptosis and cancer prognosis
- Gastric Cancer Management and Outcomes
- Hepatocellular Carcinoma Treatment and Prognosis
- Gut microbiota and health
- Cancer therapeutics and mechanisms
- Cancer Cells and Metastasis
- Immune Cell Function and Interaction
- Metastasis and carcinoma case studies
- Radiomics and Machine Learning in Medical Imaging
- Chromatin Remodeling and Cancer
- Cancer-related Molecular Pathways
- RNA modifications and cancer
Chinese Academy of Medical Sciences & Peking Union Medical College
2016-2025
Peking Union Medical College Hospital
2014-2025
Zhengzhou Children's Hospital
2025
Zhengzhou University
2020-2025
Inner Mongolia University
2025
Ministry of Agriculture and Rural Affairs
2025
Fudan University Shanghai Cancer Center
2018-2024
Affiliated Hospital of Youjiang Medical University for Nationalities
2021-2024
Gansu Provincial Hospital
2024
Breast Cancer Research Foundation
2024
Tumor mutational burden (TMB), as measured by whole-exome sequencing (WES) or a cancer gene panel (CGP), is associated with immunotherapy responses. However, whether TMB estimated circulating tumor DNA in blood (bTMB) clinical outcomes of remains to be explored.To explore the optimal size and algorithm design CGP for estimation, evaluate reliability, further validate feasibility bTMB actionable biomarker immunotherapy.In this cohort study, named NCC-GP150 was designed virtually validated...
IntroductionProgrammed death receptor-1 (PD-1) inhibitors have shown efficacy in first-line treatment of NSCLC; however, evidence PD-1 inhibitor as neoadjuvant is limited. This a phase 1b study to evaluate the safety and outcome setting.MethodsTreatment-naive patients with resectable NSCLC (stage IA–IIIB) received two cycles sintilimab (200 mg, intravenously, day 1 out 22). Operation was performed between 29 43. Positron emission tomography–computed tomography scans were obtained at baseline...
IntroductionData on immuno-oncology agents in Chinese patients are limited despite a need for new therapies. We evaluated the efficacy and safety of nivolumab predominantly patient population with previously treated NSCLC.MethodsCheckMate 078 was randomized, open-label, phase III clinical trial from China, Russia, Singapore squamous or nonsquamous NSCLC that had progressed during/after platinum-based doublet chemotherapy (ClinicalTrials.gov: NCT02613507). Patients EGFR/ALK alterations were...
<h3>Importance</h3> This study demonstrates that tislelizumab in combination with chemotherapy is associated improved progression-free survival (PFS) patients advanced squamous non–small-cell lung cancer (sq-NSCLC). <h3>Objective</h3> To assess the efficacy and safety/tolerability of plus vs alone as first-line treatment for sq-NSCLC. <h3>Design, Setting, Participants</h3> open-label, randomized phase 3 clinical trial was conducted at 46 sites China between July 2018 June 2019 included...
The phase III ADAURA (ClinicalTrials.gov identifier: NCT02511106) primary analysis demonstrated a clinically significant disease-free survival (DFS) benefit with adjuvant osimertinib versus placebo in EGFR-mutated stage IB-IIIA non-small-cell lung cancer (NSCLC) after complete tumor resection (DFS hazard ratio [HR], 0.20 [99.12% CI, 0.14 to 0.30];
Abstract T-cell receptor (TCR)–based biomarkers might predict patient response to immune checkpoint blockade (ICB) but need further exploration and validation for that use. We sequenced complementarity-determining region 3 of TCRβ chains isolated from PD-1+ CD8+ T cells investigate its value predicting the anti–programmed cell death 1 (PD-1)/PD-ligand (PD-L1) therapy in patients with non–small lung cancer (NSCLC). Two independent cohorts (cohort A, n = 25; cohort B, 15) were used as...
Abstract Biomarkers such as programmed death receptor 1 ligand (PD-L1) expression, tumor mutational burden (TMB), and high microsatellite instability are potentially applicable to predict the efficacy of immune checkpoint blockade (ICB). However, several challenges defining cut-off value, test platform uniformity, low frequencies limit their broad clinical application. Here we identify comutations in DNA damage response (DDR) pathways homologous recombination repair mismatch (HRR-MMR) or HRR...
Tislelizumab, an anti-programmed cell death protein-1 antibody, was specifically engineered to minimize FcɣR macrophage binding abrogate antibody-dependent phagocytosis. Compared with chemotherapy alone, tislelizumab plus may improve clinical outcomes in patients advanced nonsquamous NSCLC (nsq-NSCLC). In this open-label phase 3 trial (RATIONALE 304; NCT03663205), histologically confirmed stage IIIB or IV nsq-NSCLC were randomized (2:1) receive either arm A: platinum (carboplatin cisplatin)...
<h3>Importance</h3> The role of postoperative radiotherapy (PORT) has not been well defined in resected pIIIA-N2 non–small cell lung cancer (NSCLC). <h3>Objective</h3> To evaluate the effect PORT using modern techniques on survival and safety patients with NSCLC after complete resection adjuvant chemotherapy. <h3>Design, Setting, Participants</h3> PORT-C randomized clinical trial was conducted 394 treated 4 cycles platinum-based chemotherapy between January 2009 December 2017. Data were...
The CHOICE-01 study investigated the efficacy and safety of toripalimab in combination with chemotherapy as a first-line treatment for advanced non-small-cell lung cancer (NSCLC).Patients (N = 465) treatment-naive, NSCLC without EGFR/ALK mutations were randomly assigned 2:1 to receive 240 mg (n 309) or placebo 156) once every 3 weeks 4-6 cycles, followed by maintenance plus standard care. Stratification factors included programmed death ligand-1 expression status, histology, smoking status....
Abstract Small-cell lung cancer (SCLC) is the most aggressive and lethal subtype of cancer, for which, better understandings its biology are urgently needed. Single-cell sequencing technologies provide an opportunity to profile individual cells within tumor microenvironment (TME) investigate their roles in tumorigenic processes. Here, we performed high-precision single-cell transcriptomic analysis ~5000 from primary tumors (PTs) matched normal adjacent tissues (NATs) 11 SCLC patients,...
Abstract Aims Increasing evidence implicates the microbiome as a susceptibility factor for ischaemic stroke (IS). Interpretation of this is difficult, composition influenced by various factors and might affect differently in IS subtypes. We aim to determine if specific gut causally associated with subtypes suggest potential approaches prevention. Methods results conducted two-sample Mendelian randomization (MR) analysis test causal relationship between For exposure data, we extracted genetic...
Tebotelimab, a bispecific PD-1×LAG-3 DART molecule that blocks both PD-1 and LAG-3, was investigated for clinical safety activity in phase 1 dose-escalation cohort-expansion trial patients with solid tumors or hematologic malignancies disease progression on previous treatment. Primary endpoints were maximum tolerated dose of tebotelimab when administered as single agent (n = 269) combination the anti-HER2 antibody margetuximab 84). Secondary included anti-tumor activity. In advanced cancer...